Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML gilead.com ↗
2023-07-21
Gilead Sciences
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS gilead.com ↗
2022-04-11
Gilead Sciences
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies gilead.com ↗
2022-01-25
Gilead Sciences
Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine gilead.com ↗
2020-12-06
Gilead Sciences
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients gilead.com ↗
2020-09-15
Gilead Sciences
Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome gilead.com ↗
2020-05-29
Gilead Sciences
Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia gilead.com ↗
Evidence & citations 9 cited values
Every value below carries the sentence it was read from.
38 sources stand behind the page.
Field
Value
Cited text
Known as
Magrolimab
“Magrolimab (ONO-7913) is an anti-cluster of differentiation 47 (CD47) monoclonal antibody.” PMID 41888930 ↗Mar 202629
“PURPOSE: To evaluate the safety, pharmacokinetics, and pharmacodynamics of Hu5F9-G4 (5F9), a humanized IgG4 antibody that targets CD47 to enable phagocytosis.” PMID 30811285 ↗Feb 2019
Known as
Hu5F9-G4
“Participants will receive atezolizumab and magrolimab (Hu5F9-G4) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated...” NCT03869190 ↗4